← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Eli Lilly LLY $1.12T	3,905	-11	-0.3%	$584B
2	2 Amgen AMGN $235B	2,827	-31	-1%	$119B
3	3 Pfizer PFE $168B	2,820	+4	+0.1%	$92.5B
4	4 McKesson MCK $116B	1,837	+43	+2%	$82.6B
5	5 Becton Dickinson BDX $52.8B	1,485	-35	-2%	$48.3B
6	6 Novo Nordisk NVO $173B	1,400	-84	-6%	$16.7B
7	7 AstraZeneca AZN $259B	1,290	+66	+5%	$37.9B
8	8 Regeneron Pharmaceuticals REGN $82B	1,246	+43	+4%	$49B
9	9 ResMed RMD $34.1B	950	+30	+3%	$25.1B
10	10 Conagra Brands CAG $6.77B	773	-63	-8%	$7.54B
11	11 West Pharmaceutical WST $27B	758	+28	+4%	$18B
12	12 Lamb Weston LW $7.47B	625	+4	+0.6%	$7.16B
13	13 DaVita DVA $12.1B	563	-30	-5%	$8.93B
14	14 Teva Pharmaceutical Industries Limited TEVA $47.9B	553	+11	+2%	$13.3B
15	15 Hims & Hers Health HIMS $6.85B	512	+1	+0.2%	$11.3B
16	16 BellRing Brands BRBR $1.05B	437	-48	-10%	$4.53B
17	17 Viking Therapeutics VKTX $3.48B	371	-21	-5%	$1.87B
18	18 Embecta EMBC $365M	354	-6	-2%	$791M
19	19 Madrigal Pharmaceuticals MDGL $10.6B	352	+47	+15%	$10.7B
20	20 Inspire Medical Systems INSP $2.03B	325	-31	-9%	$2.31B
21	21 DELISTED Akero Therapeutics AKRO	265	+8	+3%	$4.34B
22	22 Biohaven BHVN $1.73B	264	+15	+6%	$1.26B
23	23 Rhythm Pharmaceuticals RYTM $6.06B	264	+37	+16%	$7.2B
24	24 Amphastar Pharmaceuticals AMPH $1.12B	243	-2	-0.8%	$873M
25	25 Scholar Rock SRRK $4.95B	241	+6	+3%	$4.32B